Display options
Cite
Gliozzi M, Scarano F, Musolino V, et al. Paradoxical effect of fat diet in matrix metalloproteinases induced mitochondrial dysfunction in diabetic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2021;22(4):268-278doi: 10.2459/JCM.0000000000001046.
Gliozzi, M., Scarano, F., Musolino, V., Carresi, C., Scarcella, A., Nucera, S., Scicchitano, M., Ruga, S., Bosco, F., Maiuolo, J., Macrì, R., Zito, M. C., Oppedisano, F., Guarnieri, L., Mollace, R., Palma, E., Muscoli, C., & Mollace, V. (2021). Paradoxical effect of fat diet in matrix metalloproteinases induced mitochondrial dysfunction in diabetic cardiomyopathy. Journal of cardiovascular medicine (Hagerstown, Md.), 22(4), 268-278. https://doi.org/10.2459/JCM.0000000000001046
Gliozzi, Micaela, et al. "Paradoxical effect of fat diet in matrix metalloproteinases induced mitochondrial dysfunction in diabetic cardiomyopathy." Journal of cardiovascular medicine (Hagerstown, Md.) vol. 22,4 (2021): 268-278. doi: https://doi.org/10.2459/JCM.0000000000001046
Gliozzi M, Scarano F, Musolino V, Carresi C, Scarcella A, Nucera S, Scicchitano M, Ruga S, Bosco F, Maiuolo J, Macrì R, Zito MC, Oppedisano F, Guarnieri L, Mollace R, Palma E, Muscoli C, Mollace V. Paradoxical effect of fat diet in matrix metalloproteinases induced mitochondrial dysfunction in diabetic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2021 Apr 01;22(4):268-278. doi: 10.2459/JCM.0000000000001046. PMID: 33633042.
Copy Download .nbib Format: NLM
Share it on

J Cardiovasc Med (Hagerstown). 2021 Apr 01;22(4):268-278. doi: 10.2459/JCM.0000000000001046.

Paradoxical effect of fat diet in matrix metalloproteinases induced mitochondrial dysfunction in diabetic cardiomyopathy.

Journal of cardiovascular medicine (Hagerstown, Md.)

Micaela Gliozzi, Federica Scarano, Vincenzo Musolino, Cristina Carresi, Antonino Scarcella, Saverio Nucera, Miriam Scicchitano, Stefano Ruga, Francesca Bosco, Jessica Maiuolo, Roberta Macrì, Maria Caterina Zito, Francesca Oppedisano, Lorenza Guarnieri, Rocco Mollace, Ernesto Palma, Carolina Muscoli, Vincenzo Mollace

Affiliations

  1. Institute of Research for Food Safety & Health (IRC-FSH), University 'Magna Graecia' of Catanzaro.
  2. Nutramed Scarl, Roccelletta di Borgia, Borgia, Catanzaro, Italy.

PMID: 33633042 DOI: 10.2459/JCM.0000000000001046

Abstract

AIMS: Diabetic cardiomyopathy represents the main cause of death among diabetic people. Despite this evidence, the molecular mechanisms triggered by impaired glucose and lipid metabolism inducing heart damage remain unclear. The aim of our study was to investigate the effect of altered metabolism on the early stages of cardiac injury in experimental diabetes.

METHODS: For this purpose, rats were fed a normocaloric diet (NPD) or a high fat diet (HFD) for up to 12 weeks. After the fourth week, streptozocin (35 mg/kg) was administered in a subgroup of both NPD and HFD rats to induce diabetes. Cardiac function was analysed by echocardiography. Matrix metalloproteinases (MMPs) activity and intracellular localization were assessed through zymography and immunofluorescence, whereas apoptotic and oxidative markers by immunohistochemistry and western blot.

RESULTS: Hyperglycaemia or hyperlipidaemia reduced ejection fraction and fractional shortening as compared with control. Unexpectedly, cardiac dysfunction was less marked in diabetic rats fed a hyperlipidaemic diet, suggesting an adaptive response of the myocardium to hyperglycaemia-induced injury. This response was characterized by the inhibition of N-terminal truncated-MMP-2 translocation from endoplasmic reticulum into mitochondria and by superoxide anion overproduction observed in cardiomyocytes under hyperglycaemia.

CONCLUSION: Overall, these findings suggest novel therapeutic targets aimed to counteract mitochondrial dysfunction in the onset of diabetic cardiomyopathy.

Copyright © 2020 Italian Federation of Cardiology - I.F.C. All rights reserved.

References

  1. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Therapy 2014; 142:375–415. - PubMed
  2. Maytin M, Leopold J, Loscalzo J. Oxidant stress in vasculature. Curr Atheroscler Rep 1999; 1:156–164. - PubMed
  3. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000; 85:2970–2973. - PubMed
  4. Dandona P, Mohanty P, Hamouda W, et al. Inhibitory effect of a two day fast on reactive oxygen species (ROS) generation by leucocytes and plasma ortho-tyrosine and meta-tyrosine concentrations. J Clin Endocrinol Metab 2001; 86:2899–2902. - PubMed
  5. Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces. inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52:2882–2887. - PubMed
  6. Carlsson C, Borg LA, Welsh N. Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in vitro. Endocrinology 1999; 140:3422–3428. - PubMed
  7. Victor VM, Rocha M, Herance R, Hernandez-Mijares A. Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr Pharm Des 2011; 17:3947–3958. - PubMed
  8. Sugamura K, Keaney JF. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 2011; 51:978–992. - PubMed
  9. Balaban RS. Perspectives on: SGP symposium on mitochondrial physiology and medicine: metabolic homeostasis of the heart. J Gen Physiol 2012; 139:407–414. - PubMed
  10. Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 2009; 81:449–456. - PubMed
  11. Sun D, Li S, Wu H, et al. Oncostatin M protects against cardiac ischemia/reperfusion injury in diabetic mice by regulating apoptosis, mithocondrial biogenesis and insulin sensitivity. J Cell Mol Med 2015; 19:1296–1307. - PubMed
  12. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85:1–31. - PubMed
  13. Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Phisiology 2013; 28:391–403. - PubMed
  14. Lin HB, Sharma K, Bialy D, et al. Inhibition of MMP-2 expression affects metabolic enzyme expression levels: proteomic analysis of rat cardiomyocytes. J proteomics 2014; 106:74–85. - PubMed
  15. Lovett DH, Mahimkar R, Raffai RL, et al. N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One 2013; 8:e68154. - PubMed
  16. Buki A, Okonkwo DO, Wang KK, Povlishock JT. Cytochrome c release and caspase activation in traumatic axonal injury. J Neurosci 2000; 20:2825–2834. - PubMed
  17. Ferhatovic L, Banozic A, Kostic S, et al. Expression of calcium/calmodulin-dependent protein kinase II and pain-related behavior in rat models of type 1 and type 2 diabetes. Anesth Analg 2013; 116:712–721. - PubMed
  18. Duncan JG. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 2011; 1813:1351–1359. - PubMed
  19. Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res 2010; 88:229–240. - PubMed
  20. Frati G, Schirone L, Chimenti I, et al. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyophaty. Cardiovasc Res 2017; 113:378–388. - PubMed
  21. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30:595–602. - PubMed
  22. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004; 109:2191–2196. - PubMed
  23. Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003; 42:328–335. - PubMed
  24. Scheuermann-Freestone M, Madsen PL, Manners D, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003; 107:3040–3046. - PubMed
  25. Lavie CJ, De Schutter A, Milani RV. Healthy obese versus unhealthy lean: the obesity paradox. Nat Rev Endocrinol 2015; 11:55–62. - PubMed
  26. Costanzo P, Lai D, Atkin SL. Understanding the obesity paradox in type 2 diabetes mellitus. Curr Cardiovasc Risk Rep 2015; 9:32. - PubMed
  27. Nagase H. Clendeninn NJ, Appelt K. Substrate specificity of MMPs. Cancer drug discovery and development: matrix metalloproteinase inhibitors in cancer therapy. Totowa, New Jersey: Humana Press Inc.; 2001. 39–66. - PubMed
  28. Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiol 2013; 28:391–403. - PubMed
  29. Amantea D, Russo R, Gliozzi M, et al. Early upregulation of matrix metalloproteinases following reperfusion triggers neuroinflammatory mediators in brain ischemia in rat. Int Rev Neurobiol 2007; 82:149–169. - PubMed
  30. Corasaniti MT, Russo R, Amantea D, et al. Neuroprotection by the caspase-1 inhibitor Ac-YVAD-(acyloxy)mk in experimental neuroAIDS is independent from IL-1beta generation. Cell Death Differ 2005; 12:999–1001. - PubMed
  31. Musolino V, Palus S, Tschirner A, et al. Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation. J Cachexia Sarcopenia Muscle 2016; 7:555–566. - PubMed
  32. Lewandowski KC, Banach E, Bieńkiewicz M, Lewiński A. Matrix metalloproteinases in type 2 diabetes and nondiabetic controls: effects of short-term and chronic hyperglycaemia. Arch Med Sci 2011; 2:294–303. - PubMed
  33. Lonn E, Bosch J, Yusuf S, et al. HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293:1338–1347. - PubMed
  34. Mann CJ, Perdiguero E, Kharraz Y, et al. Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle 2011; 1:21. - PubMed
  35. Chen X, Li Y. Role of matrix metalloproteinases in skeletal muscle: migration, differentiation, regeneration and fibrosis. Cell Adh Migr 2009; 3:337–341. - PubMed
  36. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463–516. - PubMed
  37. Lovett D, Mahimkar R, Raffai RL, et al. N-Terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLOS One 2013; 8:e68154. - PubMed
  38. Lovett DH, Chu C, Wang G, Ratcliffe MB, Baker AJ. A N-terminal truncated intracellular isoform of matrix metalloproteinase-2 impairs contractility of mouse myocardium. Front Physiol 2014; 5:363. - PubMed
  39. Arnaudeau S, Frieden M, Nakamura K, Castelbou C, Michalak M, Demaurex N. Calreticulin differentially modulates calcium uptake and release in the endoplasmic reticulum and mitochondria. J Biol Chem 2002; 277:46696–46705. - PubMed
  40. Kandasamy AD, Chow AK, Ali MAM, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 2009; 85:413–423. - PubMed
  41. Bryan GH, Xiaohu F, Woo JC, Richard S. MMP-2 is localized to the mitochondria-associated membrane of the heart. Am J Physiol Heart Circ Physiol 2014; 306:764–770. - PubMed
  42. Lovett DH, Mahimkar R, Raffai RL, et al. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 2012; 7:e34177. - PubMed
  43. Moshal KS, Tipparaju SM, Vacek TP, et al. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 2008; 295:890–897. - PubMed
  44. Repalli J. Translocator protein (TSPO) role in aging and Alzheimer's disease. Curr Aging Sci 2014; 7:168–175. - PubMed
  45. Papadopoulos V, Fan J, Zirkin B. Translocator protein (18 kDa): an update on its function in steroidogenesis. J Neuroendocrinol 2017; 30:e12500. - PubMed
  46. Puskás LG, Nagy ZB, Giricz Z, et al. Cholesterol diet-induced hyperlipidemia in£uences gene expression pattern of rat hearts: a DNA microarray study. FEBS Lett 2004; 562:99–104. - PubMed
  47. Paradis S, Leoni V, Caccia C, Berdeaux A, Morin D. Cardioprotection by the TSPO ligand 4’-chlorodiazepam is associated with inhibition of mitochondrial accumulation of cholesterol at reperfusion. Cardiovasc Res 2013; 98:420–427. - PubMed
  48. Colell A, García-Ruiz C, Lluis JM, Coll O, Mari M, Fernández-Checa JC. Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity. J Biol Chem 2003; 278:33928–33935. - PubMed
  49. Jašová M, Kancirová I, Waczulíková I, Ferko M. Mitochondria as a target of cardioprotection in models of preconditioning. J Bioenerg Biomembr 2017; 49:357–368. - PubMed
  50. Diogo CV, Suski JM, Lebiedzinska M, et al. Cardiac mitochondrial dysfunction during hyperglycemia: the role of oxidative stress and p66Shc signaling. Int J Biochem Cell Biol 2013; 5:114–122. - PubMed
  51. Galimov ER. The role of p66shc in oxidative stress and apoptosis. Acta Naturae 2010; 2:44–51. - PubMed
  52. Rota M, LeCapitaine N, Hosoda T, et al. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res 2006; 99:42–52. - PubMed
  53. Carresi C, Musolino V, Gliozzi M, et al. Antioxidant effect of bergamot polyphenolic fraction counteracts doxorubicin-induced cardiomyopathy: role of autophagy and c-kitposCD45negCD31neg cardiac stem cell activation. J Mol Cell Cardiol 2018; 119:10–18. - PubMed
  54. Dehghan M, Mente A, Zhang X, et al. Prospective Urban Rural Epidemiology (PURE) study investigators. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet 2017; 390:2050–2062. - PubMed
  55. Musolino V, Gliozzi M, Scarano F, et al. Bergamot polyphenols improve dyslipidemia and pathophysiological features in a mouse model of non-alcoholic fatty liver disease. Sci Rep 2020; 10:2565. - PubMed

Publication Types